Table 3 Predictors of overall survival in patients with brain metastases from breast cancer (univariate analyses)

Age at BM diagnosis

≥ 50 Vs. < 50

1.21 [0.80; 1.81]

0.329

KPS

≥ 70 vs. < 70

0.51 [0.34; 0.77]

0.0013

RTOG RPA class

III vs. I-II

1.98 [1.32; 2.98]

0.0013

Time interval (y) between primary tumor and BM diagnosis

≥ 2 vs. < 2

3.76 [0.52; 27.18]

0.968

Brain metastases

Presence of systemic metastases vs. Alone

1.52 [0.62; 3.74]

0.366

Visceral metastases

Yes vs No

1.34 [0.84; 2.11]

0.2159

Bone metastases

Yes vs No

1.07 [0.71; 1.60]

0.745

No. of BM

Multiple vs. single

1.12 [0.41; 3.06]

0.822

Nb of other metastatic sites

Multiple vs. single

1.516 [0.6148; 3.74]

0.3627

Histology

lobular and other vs. ductal

0.77 [0.34; 1.77]

0.545

Tumor HR status

Negative vs. positive

1.37 [0.91; 2.06]

0.127

HER-2 overexpression

Negative vs. positive

1.48 [0.98; 2.24]

0.0606

Trastuzumab-based therapy for HER2 overexpressing tumor

Yes vs No

0.45 [0.27; 0.75]

0.001631

HR- & HER2-

Yes vs No

2.17 [1.38; 3.43]

0.0006

SBR grade

3 vs. 1-2

1.59 [1.00; 2.52]

0.0484

LDH (U/L)

> 500 vs. ≤ 500

2.01 [1.27; 3.16]

0.0026

Lymphocyte count

> 700 vs. ≤ 700

0.58 [0.37; 0.89]

0.0138

Total radiation dose (Gy)

> 30 vs. ≤ 30

1.54 [0.49; 4.91]

0.463